We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

By LabMedica International staff writers
Posted on 29 Oct 2014
A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. More...


Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published this groundbreaking finding October 17, 2014, in the international journal Science. By means of some of the shortest laser pulses, the researchers employed strobe lighting to monitor the ultra-fast movement of the electrons within a nanometer-sized molecule of amino acid. The resulting oscillations—lasting for 4,300 attoseconds—amount to the fastest process ever observed in a biologic structure.

Dr. Greenwood said, “Explaining how electrons move on the nanoscale is crucial for the understanding of a range of processes in matter as it is this charge which initiates many biological, chemical, and electrical processes. For instance, the charge produced from the interaction of ionizing radiation with DNA and its subsequent ultra-fast movement can lead to damage of the DNA and cell death which is exploited in radiotherapy to treat cancer. This knowledge is therefore important for understanding the action of radiotherapy beams in cancer treatment. Being able to describe how light interacts with electrons on these timescales could also lead to improvements in how light is converted into electricity in solar cells or faster microprocessors, which use light rather than electrical signals for switching transistors.”

The research was performed by Queen’s School of Mathematics and Physics in collaboration with the Politecnico Milano (Italy), the Universidad Autónoma of Madrid (Spain), University of Trieste (Italy), and Institute of Photonics and Nanotechnologies IFN-CNR (Padua, Italy).

Dr. Greenwood concluded, “This research will hopefully open up the emerging field of attosecond science which seeks to understand how ultrafast electrons play a key role in chemistry, biology and nanotechnology. This is very early research but this new field of ultrafast light-induced electronics is likely to have an impact in biology, chemistry and materials in the next five to 10 years. Practical applications down the line may include improvements in cancer radiotherapy, highly efficient solar cells, and much faster computer processors.”

Related Links:

Queen’s University Belfast
Politecnico Milano 
Universidad Autónoma of Madrid 



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.